Expert Insights

In part one of this interview, Charles Loprinzi, MD, Mayo Clinic, highlights some non-estrogenic approaches to hot flash management for patients with breast cancer, presented at the 39th Annual Miami Breast Cancer Conference.

Robert Peter Gale, MD, PhD, DSc (Hon), FACP, FRCP, FRSM, highlights transplants and cell therapies, including HCT and CAR T-cells, for patients with CLL.

Jan A. Burger, MD, PhD, highlights a study on the activation and expansion of T follicular helper cells in co-cultures of patients with CLL.

Geoffrey L. Uy, MD, reviews the safety and efficacy results from a phase 1b study on lower-dose CPX-351 plus venetoclax as a first-line treatment for patients with AML who are unfit for intensive chemotherapy, presented at ASH 2021.

Mitchell E. Horwitz, MD, discusses results from a phase 3 trial evaluating the efficacy of omidubicel compared to standard umbilical cord blood transplantation for patients with GVHD.

Uday R Popat, MD, overviews the long-term disease outcomes from a phase 2 prospective clinical trial on myeloablative fractionated busulfan with fludarabine in older patients with hematologic malignancies.

In an interview with Oncology Learning Network, Saad Z. Usmani, MD, spoke on the findings and clinical significance of a phase 1 study on teclistamab, a BCMA and CD3 bispecific antibody, in patients with R/R MM.

Hun Ju Lee, MD, reviews a phase 1b/2 study of cirmtuzumab and ibrutinib for patients with MCL or CLL.

Dr Jacob highlights the progress of SunRISe-1: a phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk non–muscle-invasive bladder cancer unresponsive to BCG who are ineligible for or...